Edgewise Therapeutics is a biopharmaceutical firm focused on creating treatments for muscle disorders. Its flagship product, EDG-5506, is an oral medication currently in Phase II trials, aimed at treating dystrophinopathies such as Duchenne and Becker muscular dystrophy. The company is also working on EDG-7500 for severe cardiac disorders, now in Phase I trials. Additionally, Edgewise is developing a range of precision medicine candidates targeting specific muscle proteins to combat genetically defined muscle conditions. Founded in 2017, the company is based in Boulder, Colorado.
Recent insider buying has been highlighted by purchases by Warren Buffett, Jack Ma, Carlos Slim, and John Paulson. Biotechs tempted insiders, as did public offerings.
